In January a government investigation related to our U.S. marketing and promotional practices with respect to Zyprexa®, we entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services Office of the Inspector General, which requires us to maintain our compliance program and to undertake a set of defined corporate integrity obligations for five years.